Prostate-specific antigen doubling time as a prognostic marker in prostate cancer

被引：0
|
作者：
James A Eastham
机构：
[1] surgeon in the Department of Urology at Memorial Sloan–Kettering Cancer Center,
来源：
Nature Clinical Practice Urology | 2005年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
There is much debate surrounding the suitability and utility of different prognostic markers in prostate cancer. PSA doubling time (PSADT) has become an important marker in predicting the response to salvage radiotherapy and progression to metastatic disease in men with biochemical failure following local therapy. The methods of calculating PSADT and its use as a prognostic marker are discussed in this review by James Eastham.
引用
收藏
页码：482 / 491
页数：9
相关论文
共 50 条
  • [21] Using prostate-specific antigen doubling time in clinical practice
    Lee, Andrew K.
    D'Amico, Anthony V.
    BJU INTERNATIONAL, 2007, 100 (02) : 243 - 244
  • [22] Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer
    Semeniuk, Ross C.
    Venner, Peter M.
    North, Scott
    UROLOGY, 2006, 68 (03) : 565 - 569
  • [23] Re: Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time as Predictors for Prostate Cancer
    Thalmann, George N.
    EUROPEAN UROLOGY, 2009, 56 (05) : 884 - 885
  • [24] Economic impact of prostate-specific antigen doubling time in patients with hormone-refractory prostate cancer
    Mulani, P
    Botteman, M
    Hay, JW
    Cifaldi, M
    VALUE IN HEALTH, 2005, 8 (03) : 346 - 346
  • [25] Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality
    Cirulli, Giuseppe Ottone
    Davis, Matthew
    Stephens, Alex
    Chiarelli, Giuseppe
    Finati, Marco
    Chase, Morrison
    Tinsley, Shane
    Arora, Sohrab
    Sood, Akshay
    Lughezzani, Giovanni
    Buffi, Nicolo
    Carrieri, Giuseppe
    Salonia, Andrea
    Briganti, Alberto
    Montorsi, Francesco
    Rogers, Craig
    Abdollah, Firas
    CANCER, 2025, 131 (01)
  • [26] Prostate-specific antigen (PSA): A tumor marker in the diagnosis of prostate cancer
    Ohlendorf D.
    Wanke E.M.
    Braun M.
    Oremek G.M.
    Groneberg D.A.
    Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 2017, 67 (4) : 221 - 223
  • [27] Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer
    Wolff, JM
    Bares, R
    Jung, PK
    Buell, U
    Jakse, G
    UROLOGIA INTERNATIONALIS, 1996, 56 (03) : 169 - 173
  • [28] Prostate-specific antigen and prostate cancer
    Rosalki, SB
    Rutherford, FJ
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, 54 (09) : 611 - 613
  • [29] Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer
    Tkac, Jan
    Gajdosova, Veronika
    Hroncekova, Stefania
    Bertok, Tomas
    Hires, Michal
    Jane, Eduard
    Lorencova, Lenka
    Kasak, Peter
    INTERFACE FOCUS, 2019, 9 (02)
  • [30] Prostate-specific antigen value as a marker in breast cancer
    Narita, D
    Cimpean, AM
    Anghel, A
    Raica, M
    NEOPLASMA, 2006, 53 (02) : 161 - 167
12345